VGX International to initiate Phase I clinical studies of VGX-1027

VGX International is planning to conduct its Phase I clinical studies of VGX-1027, a novel small molecule compound with potent anti-inflammatory activity, in healthy volunteers jointly with its affiliate, VGX Pharmaceuticals after getting the approval of an investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) on January 12.

VGX-1027 is the Company's lea...